Literature DB >> 22460751

Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ).

Salvatore L Ruggiero1.   

Abstract

Bisphosphonates are a class of agents used to treat osteoporosis and malignant bone metastases. Despite these benefits, osteonecrosis of the jaws has recently emerged as a significant complication in a subset of patients receiving these drugs. Based on a growing number of case reports and institutional reviews, bisphosphonate therapy may cause exposed and necrotic bone that is isolated to the jaw. This complication usually presents following simple dentoalveolar surgery and can cause a significant adverse effect on the quality of life for most patients. The pathogenesis for this complication appears to be related to the profound inhibition of osteoclast function and bone remodeling. This report will review the clinical signs and symptoms and risks associated with this new complication and provide a guideline for establishing a stage-specific diagnosis of BRONJ.

Entities:  

Year:  2007        PMID: 22460751      PMCID: PMC2781180     

Source DB:  PubMed          Journal:  Clin Cases Miner Bone Metab        ISSN: 1724-8914


  36 in total

1.  Long-term safety of bisphosphonates.

Authors:  Susan M Ott
Journal:  J Clin Endocrinol Metab       Date:  2005-03       Impact factor: 5.958

2.  Bisphosphonates and osteonecrosis of the jaw.

Authors:  Patrick M Purcell; Ian W Boyd
Journal:  Med J Aust       Date:  2005-04-18       Impact factor: 7.738

3.  Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.

Authors:  Salvatore L Ruggiero; John Fantasia; Eric Carlson
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2006-07-31

4.  Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial.

Authors:  P Ravn; M Bidstrup; R D Wasnich; J W Davis; M R McClung; A Balske; C Coupland; O Sahota; A Kaur; M Daley; G Cizza
Journal:  Ann Intern Med       Date:  1999-12-21       Impact factor: 25.391

5.  Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.

Authors:  Cesar A Migliorati; Mark M Schubert; Douglas E Peterson; Luis Marcelo Seneda
Journal:  Cancer       Date:  2005-07-01       Impact factor: 6.860

Review 6.  Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.

Authors:  Martha Q Lacy; Angela Dispenzieri; Morie A Gertz; Philip R Greipp; Kimberly L Gollbach; Suzanne R Hayman; Shaji Kumar; John A Lust; S Vincent Rajkumar; Stephen J Russell; Thomas E Witzig; Steven R Zeldenrust; David Dingli; P Lief Bergsagel; Rafael Fonseca; Craig B Reeder; A Keith Stewart; Vivek Roy; Robert J Dalton; Alan B Carr; Deepak Kademani; Eugene E Keller; Christopher F Viozzi; Robert A Kyle
Journal:  Mayo Clin Proc       Date:  2006-08       Impact factor: 7.616

7.  Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.

Authors:  R L Theriault; A Lipton; G N Hortobagyi; R Leff; S Glück; J F Stewart; S Costello; I Kennedy; J Simeone; J J Seaman; R D Knight; K Mellars; M Heffernan; D J Reitsma
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

8.  Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.

Authors:  G N Hortobagyi; R L Theriault; A Lipton; L Porter; D Blayney; C Sinoff; H Wheeler; J F Simeone; J J Seaman; R D Knight; M Heffernan; K Mellars; D J Reitsma
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

9.  American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

Authors:  James R Berenson; Bruce E Hillner; Robert A Kyle; Ken Anderson; Allan Lipton; Gary C Yee; J Sybil Biermann
Journal:  J Clin Oncol       Date:  2002-09-01       Impact factor: 44.544

10.  American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.

Authors:  B E Hillner; J N Ingle; J R Berenson; N A Janjan; K S Albain; A Lipton; G Yee; J S Biermann; R T Chlebowski; D G Pfister
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

View more
  21 in total

1.  The effects of bisphosphonates on osteonecrosis of jaw bone: a stem cell perspective.

Authors:  Hüseyin Abdik; Ezgi Avşar Abdik; Selami Demirci; Ayşegül Doğan; Duygu Turan; Fikrettin Şahin
Journal:  Mol Biol Rep       Date:  2018-12-01       Impact factor: 2.316

Review 2.  Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ).

Authors:  Victoria Rollason; Alexandra Laverrière; Laura C I MacDonald; Tanya Walsh; Martin R Tramèr; Nicole B Vogt-Ferrier
Journal:  Cochrane Database Syst Rev       Date:  2016-02-26

3.  Why worry about bisphosphonate-related osteonecrosis of the jaw? A guide to diagnosis, initial management, and referral of patients.

Authors:  Karl Fb Payne; Alexander Mc Goodson; Arpan S Tahim; Imran Rafi; Peter A Brennan
Journal:  Br J Gen Pract       Date:  2017-07       Impact factor: 5.386

4.  In vivo effects of zoledronic acid on oral mucosal epithelial cells.

Authors:  E Allam; Mr Allen; T-M Chu; A Ghoneima; L Jack Windsor
Journal:  Oral Dis       Date:  2010-09-23       Impact factor: 3.511

Review 5.  Interventions for managing medication-related osteonecrosis of the jaw.

Authors:  Natalie H Beth-Tasdogan; Benjamin Mayer; Heba Hussein; Oliver Zolk; Jens-Uwe Peter
Journal:  Cochrane Database Syst Rev       Date:  2022-07-12

6.  Long-Term Ligature-Induced Periodontitis Exacerbates Development of Bisphosphonate-Related Osteonecrosis of the Jaw in Mice.

Authors:  Drake Winslow Williams; Katie Ho; Allison Lenon; Sol Kim; Terresa Kim; Yousang Gwack; Reuben H Kim
Journal:  J Bone Miner Res       Date:  2022-06-09       Impact factor: 6.390

7.  Tooth extraction in osteoporotic patients taking oral bisphosphonates.

Authors:  M Mozzati; V Arata; G Gallesio
Journal:  Osteoporos Int       Date:  2013-01-04       Impact factor: 4.507

8.  Ninety-one osteoporosis patients affected with bisphosphonate-related osteonecrosis of the jaw: a case series.

Authors:  E Mercer; T Norton; S Woo; N Treister; T B Dodson; D H Solomon
Journal:  Calcif Tissue Int       Date:  2013-06-12       Impact factor: 4.333

9.  Oral bisphosphonate related osteonecrosis of the jaw: a challenging adverse effect.

Authors:  Ilke Coskun Benlidayi; Rengin Guzel
Journal:  ISRN Rheumatol       Date:  2013-05-16

Review 10.  Interventions for managing medication-related osteonecrosis of the jaw.

Authors:  Natalie H Beth-Tasdogan; Benjamin Mayer; Heba Hussein; Oliver Zolk
Journal:  Cochrane Database Syst Rev       Date:  2017-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.